The research activities of the INRASTES Radiopharmacy teams aim at the development of novel radioactive drugs, termed ‘’radiopharmaceuticals’’, for application in medical diagnosis and therapy. Complementary efforts of the three involved teams pertaining to the synthesis of new radiolabeled compounds and their precursors and their evaluation in preclinical disease models literally harness the unique properties of radioactive elements to address unmet medical needs. Notably, the Radiopharmacy research activities have been successful in identifying attractive candidates for use in diagnostic imaging with PET and SPECT as well as for radionuclide therapy of disease, attracting the interest of the private sector. At the same time they have been instrumental in deepening our knowledge on the complex biochemical background of cancer and other pathologies.
